Olga Leonardi, MD
Endocrinology · New York, NYNPI 1982666004
Payments from drug & device makers
Across 489 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Novo Nordisk$2K
- AstraZeneca$934
- Sanofi-aventis U.S. LLC$525
- Abbott$512
- Boehringer Ingelheim$424
- plus $3K from 29 others
What the payments were for
- Food & beverage$10,33699%
- Education$921%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 161 | $2,672 |
| Novo Nordisk | 115 | $2,103 |
| AstraZeneca(2 entities) | 19 | $934 |
| Sanofi-aventis U.S. LLC | 16 | $525 |
| Abbott | 13 | $512 |
| Boehringer Ingelheim | 15 | $424 |
| Amgen(2 entities) | 15 | $394 |
| Radius Health, Inc. | 17 | $359 |
| AbbVie | 14 | $324 |
| Mannkind Corporation | 11 | $267 |
| Insulet Corporation | 10 | $188 |
| Pfizer | 9 | $182 |
| IBSA Pharma Inc. | 11 | $179 |
| Sequel Med Tech, LLC | 1 | $172 |
| Amneal Pharmaceuticals LLC | 6 | $130 |
| Merck | 6 | $120 |
| Medtronic(2 entities) | 5 | $110 |
| Antares Pharma, Inc. | 5 | $108 |
| Acella Pharmaceuticals, LLC | 4 | $87 |
| Corcept Therapeutics | 3 | $79 |
| Dexcom, Inc. | 4 | $76 |
| Aytu Biopharma, Inc. | 3 | $65 |
| Currax Pharmaceuticals LLC | 4 | $65 |
| Bayer | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Novartis | 3 | $53 |
| Recordati_rare_diseases_inc. | 3 | $52 |
| Vivus LLC | 2 | $45 |
| Acerus Pharmaceuticals Corporation | 2 | $27 |
| Intra-sana Laboratories | 1 | $23 |
| RGH Enterprises LLC | 1 | $23 |
| Embecta Corp. | 1 | $22 |
| Eisai Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,487 in reported general payments places this provider in the 95th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 262 | $361,812 |
| TrulicityDulaglutide | 84 | $140,990 |
| OzempicSemaglutide | 78 | $122,196 |
| FarxigaDapagliflozin Propanediol | 45 | $66,620 |
| JardianceEmpagliflozin | 50 | $52,231 |
| JanuviaSitagliptin Phosphate | 31 | $42,655 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $30,031 |
| ProliaDenosumab | 16 | $27,455 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $24,063 |
| TradjentaLinagliptin | 15 | $20,237 |
| Humalog Kwikpen U-100Insulin Lispro | 67 | $16,400 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $14,269 |
| SynthroidLevothyroxine Sodium | 146 | $13,459 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,632 |
| Novolog FlexpenInsulin Aspart | 48 | $12,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,672 | $502,801346 claims |
| Novo NordiskOzempic | $2,103 | $122,19678 claims |
| MerckJanuvia, Janumet Xr | $120 | $72,68659 claims |
| Boehringer IngelheimJardiance, Tradjenta | $424 | $72,46865 claims |
| AstraZenecaFarxiga | $934 | $66,62045 claims |
| AmgenProlia | $394 | $27,45516 claims |
| AbbVieSynthroid | $324 | $13,459146 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $130 | $3,867323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 endocrinology providers in New York.
Other endocrinology in New York
- Philip RabitoNew York$712K
- Lauren GoldenNew York$729
- Julia Vargas-JerezNew York$590
- Sananda MoctezumaNew York$121
- Marcia KalinNew York$0
- Peter GouldenNew York$0
- Danielle BrooksNew York$0
- Nandini NairNew York$0
- Martin BarandesNew York$0
- Sharon WardlawNew York$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.